Navigation Links
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Date:10/27/2008

p>

About LoSEASONIQUE(R)

LoSEASONIQUE(R) is a lower dose extended cycle oral contraceptive indicated for the prevention of pregnancy. The clinical data supporting the LoSEASONIQUE(R) NDA resulted from a 12-month, multi-centered, open label clinical trial that concluded in June 2007. The clinical trial involved over 2,100 female subjects between the ages of 18 and 41 at 56 sites throughout the United States, and subjects completed an equivalent of nearly 21,000 28-day cycles of exposure.

The most common adverse events in the clinical trial were headache, irregular and/or heavy uterine bleeding, dysmenorrhea, nausea and/or vomiting, and back pain.

Important Information About Oral Contraceptives

It is estimated that more than 16 million women currently take oral contraceptives in the United States. Oral contraceptives are not for every woman. Serious as well as minor side effects have been reported with the use of hormonal contraceptives. Serious risks include blood clots, stroke, and heart attack. Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35 years. Oral contraceptives do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 26 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S. For more information, visit http://www.barrla
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
4. FDA Approves Fougeras Clotrimazole Cream USP 1%
5. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
6. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
7. Signalife Board Approves Merger
8. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
11. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City ... firms and animal health companies to hear from animal health companies with the ... also received licensing agreements or distribution contracts. This meeting is one of ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... six-month periods ended June 30, 2015. Biorem,s complete second quarter financial ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , ... 2014 , 2015 , 2014 Revenue , ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... Boston, MA (PRWEB) , ... August 27, 2015 , ... ... the United States, ranking iLab Solutions as number 1,361 in growth for the three ... part of the top 0.1% fastest-growing privately held organizations in the country. , ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Israel, April 28 ITGI Medical, Ltd.,(TASE: ITGI) ... of heterologous tissue covered stents, announced that the ... (Humanitarian Use Device),designation to Over and Under(R) and ... dissections of native coronary arteries and,Saphenous Vein Grafts. ...
... Mich., April 28 The following news advisory is ... Business Meeting - During the meeting an important development ... MichBio, Michigan,s trade association for the bioscience industry When: ... Reception , 6:30 p.m. Dinner , 7:00 p.m. Meeting ...
... also Initiates the Phase 2b ASTUTE Clinical Trial for ... Inc., a privately held biopharmaceutical company, announced that data ... treatment of patients with low-grade hepatic encephalopathy was presented ... European Association for the Study of Liver Disease (EASL) ...
Cached Biology Technology:Key Industry-Relevant Development to be Announced at MichBio's 2009 Annual Meeting on May 6 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... plague belongs to a virulent family of bacteria called ... for food poisoning. These bacteria insert into their host ... -- among other things -- disrupting the cells' normal ... cell's internal skeleton. Now, a study published by Rockefeller ...
... the Translational Genomics Research Institute (TGen) in Phoenix, ... discover a gene--called Kibra--associated with memory performance in ... develop new medicines for memory-based diseases such as ... better understanding of how memory works at the ...
... low birth weights tend to have a much lower quality of ... a study published in the latest issue of the UK-based Journal ... birth weights of 1500g or less and compared them with a ... quality of life when it came to physical, emotional, cognitive and ...
Cached Biology News:A wolf in sheep's clothing: Plague bacteria reveal one of their virulence tricks 2Affymetrix 500K array used to identify memory gene 2Very low birth weight linked to reduced quality of life in pre-school children 2
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
SDS-OutT Precipitation Reagent...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
Biology Products: